Desmoteplase

Desmoteplase is a novel, highly fibrin-specific thrombolytic agent in phase III of clinical development. In 2009, two large trials (DIAS-3 and DIAS-4) were started, and the results of these studies will determine whether desmoteplase will gain marketing authorisation as a safe and effective treatment for patients with acute ischaemic stroke. Filing with health authorities is estimated in the second quarter of 2014. The Danish pharmaceutical company, H. Lundbeck A/S (commonly known as Lundbeck), owns the worldwide rights to desmoteplase.